End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
24.88 USD | -1.50% |
|
-4.31% | +139.23% |
06-12 | Dianthus Therapeutics Secures US FDA Approval to Launch Phase 2 Study of DNTH103 in Multifocal Motor Neuropathy | MT |
06-12 | Dianthus Therapeutics Gets FDA Clearance for DNTH103 Phase 2 Trial | DJ |
Sales 2024 * | 1.78M 2.44M | Sales 2025 * | 2M 2.74M | Capitalization | 749M 1.03B |
---|---|---|---|---|---|
Net income 2024 * | -63M -86.27M | Net income 2025 * | -88M -121M | EV / Sales 2024 * | 244 x |
Net cash position 2024 * | 314M 429M | Net cash position 2025 * | 518M 710M | EV / Sales 2025 * | 115 x |
P/E ratio 2024 * |
-11.8
x | P/E ratio 2025 * |
-10
x | Employees | 53 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.16% |
1 day | -1.50% | ||
1 week | -4.31% | ||
Current month | +15.13% | ||
1 month | +1.26% | ||
3 months | -10.95% | ||
6 months | +184.34% | ||
Current year | +139.23% |
![Extreme 24.16](/images/extremecours_fleche.png)
![Extreme 19.845](/images/extremecours_fleche.png)
![Extreme 10.22](/images/extremecours_fleche.png)
![Extreme 6.58](/images/extremecours_fleche.png)
![Extreme 6.58](/images/extremecours_fleche.png)
![Extreme 6.58](/images/extremecours_fleche.png)
![Extreme 6.58](/images/extremecours_fleche.png)
Date | Price | Change | Volume |
---|---|---|---|
24-06-21 | 25.53 | -1.28% | 989,569 |
24-06-20 | 25.86 | +3.94% | 260,264 |
24-06-18 | 24.88 | -1.50% | 539,617 |
24-06-17 | 25.26 | -2.85% | 413,582 |
24-06-14 | 26 | -3.56% | 272,224 |
End-of-day quote Nasdaq, June 17, 2024
More quotes![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+139.23% | 749M | |
+15.19% | 121B | |
+19.91% | 114B | |
+8.24% | 23.61B | |
-19.80% | 20.43B | |
-16.19% | 16.55B | |
-13.45% | 16.45B | |
-44.35% | 15.59B | |
+2.13% | 13.54B | |
+66.67% | 15.19B |
- Stock Market
- Equities
- DNTH Stock